Visit https://www.peervoice.com/AZJ860 to view the entire programme with slides. After completing “Metastatic Urothelial Carcinoma: Maintaining Stable Disease”, participants will be able to: Describe the latest recommendations for first-line maintenance treatment for patients with stable metastatic urothelial carcinoma (mUC), Interpret the impact of the evidence for maintenance immunotherapy regimens in first-line mUC on treatment sequencing and long-term clinical care of the patient, Identify patients who may be eligible for first-line maintenance treatment with immunotherapy.